Core Insights - Crescent Biopharma has appointed Dr. Jan Pinkas as chief scientific officer, bringing over two decades of experience in oncology drug development [1][2] - The company is advancing its portfolio of next-generation therapeutics for solid tumors, with plans to initiate a global Phase 1 trial for CR-001 in early 2026 and an IND submission for CR-002 in mid-2026 [2][5] Company Overview - Crescent Biopharma aims to build a leading oncology company focused on developing innovative therapies for cancer patients, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates [5] - The company’s pipeline is designed to leverage advancements in cooperative PD-1 x VEGF therapies and next-generation ADCs, targeting both monotherapy and combination treatment opportunities [2][5] Leadership Background - Dr. Pinkas previously served as chief scientific officer at Pyxis Oncology, where he established preclinical research for ADC programs [3] - His experience includes significant roles at Magenta Therapeutics and ImmunoGen, where he contributed to the development of approved therapies such as ELAHERE and SARCLISA [3][4]